SA
Create Free Alerts
Day One Biopharmaceuticals, Inc.DAWNNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More
247wallst.com

Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

Pre-Market Stock Futures: Futures are trading lower as we hit the mid-point of the trading week, and while we didn't see the snapback rally that was the star of the show Monday, at least all four major indices held their own as the conflict in Iran grinds on. The Nasdaq was able to eke out... Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More.

Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen
defenseworld.net

Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen

Day One Biopharmaceuticals (NASDAQ: DAWN) executives highlighted accelerating commercial momentum for OJEMDA and outlined multiple upcoming clinical catalysts during a fireside chat at TD Cowen's 46th Annual Healthcare Conference. Charles York, the company's CFO and COO, said 2025 marked a "fantastic year" for Day One as it delivered its first full year of OJEMDA sales following

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More
247wallst.com

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More

Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday. That was the biggest spike in oil pricing since 2020. With the retreat in the black gold, the major indices did a massive... Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims and Hers, Intuit, Lowe's, Qualcomm, Rivian, Strategy and More.

Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
businesswire.com

Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
newsfilecorp.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Servier for $21.50 per share in an all-cash transaction, representing a total equity value of approximately $2.5 billion. The investigation concerns whether the Day One Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Servier. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)
prnewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

NEW YORK, March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) related to its sale to Servier Pharmaceuticals LLC.

DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com

DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) to Servier for $21.50 per share in cash. Halper Sadeh encourages Day One shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Day One and its board of directors viola.

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
globenewswire.com

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

SURESNES, France and BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.

Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
seekingalpha.com

Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth

Day One Biopharmaceuticals is maintained at a "Strong Buy" rating, driven by robust pipeline progress and multiple upcoming catalysts. The company's OJEMDA achieved FDA approval and delivered 172% year-over-year revenue growth in 2025, with label expansion efforts underway in pivotal phase 3 trial. Two novel ADC programs, Emi-Le and DAY-301, target high-value oncology indications, with key clinical data readouts expected in mid- and late 2026.

Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
seekingalpha.com

Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead

Day One Biopharmaceuticals, Inc.'s Q4 '25 came with net product revenues of $52.8M, up 36% from the prior quarter. DAWN's 2026 guidance for U.S. net product revenues of $225M-$250M implies 50% growth over 2025 at the midpoint of that guidance. Key catalysts include clinical readouts from Emi-Le and DAY-301 in 2026. A readout from FIREFLY-2 could come in mid-2027.

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
globenewswire.com

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance